Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Maari

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Dermatology and Therapy|April 22, 2021
Psoriasis Prevalence and Severity by Expert ElicitationKim A Papp, Robert Gniadecki, Jennifer Beecker, et al.
Dermatology and Therapy|December 23, 2021
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based MethodologyKim A Papp, Melinda J Gooderham, Charles W Lynde, et al.
The Journal of Allergy and Clinical Immunology|July 26, 2020
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasisHelen He, Robert Bissonnette, Jianni Wu, et al.
Journal of the American Academy of Dermatology|July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.
Allergy|September 30, 2022
Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseasesAna B Pavel, Ester Del Duca, Julia Cheng, et al.
The Journal of Investigative Dermatology|November 26, 2018
A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the SkinCorrie L Gallant-Behm, Joseph Piper, Joshua M Lynch, et al.
JAMA Dermatology|August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical TrialApril W Armstrong, Melinda Gooderham, Charles Lynde, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Allergy|August 14, 2023
Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsiesEster Del Duca, Helen He, Ying Liu, et al.
Dermatology and Therapy|April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Dermatology and Therapy|April 22, 2021
Psoriasis Prevalence and Severity by Expert ElicitationKim A Papp, Robert Gniadecki, Jennifer Beecker, et al.
Dermatology and Therapy|December 23, 2021
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based MethodologyKim A Papp, Melinda J Gooderham, Charles W Lynde, et al.
The Journal of Allergy and Clinical Immunology|July 26, 2020
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasisHelen He, Robert Bissonnette, Jianni Wu, et al.
Journal of the American Academy of Dermatology|July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.
Allergy|September 30, 2022
Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseasesAna B Pavel, Ester Del Duca, Julia Cheng, et al.
The Journal of Investigative Dermatology|November 26, 2018
A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the SkinCorrie L Gallant-Behm, Joseph Piper, Joshua M Lynch, et al.
JAMA Dermatology|August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical TrialApril W Armstrong, Melinda Gooderham, Charles Lynde, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Allergy|August 14, 2023
Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsiesEster Del Duca, Helen He, Ying Liu, et al.
Dermatology and Therapy|April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.
Pageof 5